Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review
In India, Omicron (B1.1.529), a variant of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has challenged the existing drug treatments options and available vaccines. Extensive search has been done to review updated information through original research articles, meta-analys...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Saudi Journal for Health Sciences |
| Subjects: | |
| Online Access: | http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=83;epage=90;aulast=Inder |
| _version_ | 1811211160865734656 |
|---|---|
| author | Deep Inder Seema Manak Md Faiz Akram Pawan Kumar |
| author_facet | Deep Inder Seema Manak Md Faiz Akram Pawan Kumar |
| author_sort | Deep Inder |
| collection | DOAJ |
| description | In India, Omicron (B1.1.529), a variant of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has challenged the existing drug treatments options and available vaccines. Extensive search has been done to review updated information through original research articles, meta-analysis, and case reports available at EMBASE, SCOPUS, and Google Scholar, for treatment and preventive strategies against Omicron. Excessive mutations in SARS-CoV-2 (Omicron) led to immune escape witnessed for monoclonal antibodies, leaving very limited drug options to treat Omicron infected patients. Protection offered by existing vaccines appeared as a matter of concern as far as efficacy against Omicron is concerned. Although vaccination will not prevent re-infection in actively and passively immunized individual, but will prevent serious respiratory illness and death. The current review article imparts knowledge regarding pharmacotherapeutic agents, showing promise against Omicron. The present review also highlights updated data on newer vaccine candidates for their safety and efficacy for Omicron, based on postmarketing surveillance and Phase III clinical trials across the globe. There is a need to generate more data on drugs as well as vaccines specifically targeting Omicron, in order to contain SARS-CoV-2 new variant. |
| first_indexed | 2024-04-12T05:08:04Z |
| format | Article |
| id | doaj.art-35d3a4120e4d4e2bb6923746ed039f90 |
| institution | Directory Open Access Journal |
| issn | 2278-0521 |
| language | English |
| last_indexed | 2024-04-12T05:08:04Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal for Health Sciences |
| spelling | doaj.art-35d3a4120e4d4e2bb6923746ed039f902022-12-22T03:46:49ZengWolters Kluwer Medknow PublicationsSaudi Journal for Health Sciences2278-05212022-01-01112839010.4103/sjhs.sjhs_42_22Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive reviewDeep InderSeema ManakMd Faiz AkramPawan KumarIn India, Omicron (B1.1.529), a variant of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has challenged the existing drug treatments options and available vaccines. Extensive search has been done to review updated information through original research articles, meta-analysis, and case reports available at EMBASE, SCOPUS, and Google Scholar, for treatment and preventive strategies against Omicron. Excessive mutations in SARS-CoV-2 (Omicron) led to immune escape witnessed for monoclonal antibodies, leaving very limited drug options to treat Omicron infected patients. Protection offered by existing vaccines appeared as a matter of concern as far as efficacy against Omicron is concerned. Although vaccination will not prevent re-infection in actively and passively immunized individual, but will prevent serious respiratory illness and death. The current review article imparts knowledge regarding pharmacotherapeutic agents, showing promise against Omicron. The present review also highlights updated data on newer vaccine candidates for their safety and efficacy for Omicron, based on postmarketing surveillance and Phase III clinical trials across the globe. There is a need to generate more data on drugs as well as vaccines specifically targeting Omicron, in order to contain SARS-CoV-2 new variant.http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=83;epage=90;aulast=Inderdrugs optionsimmune escapeomicronpharmacotherapyvaccines |
| spellingShingle | Deep Inder Seema Manak Md Faiz Akram Pawan Kumar Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review Saudi Journal for Health Sciences drugs options immune escape omicron pharmacotherapy vaccines |
| title | Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review |
| title_full | Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review |
| title_fullStr | Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review |
| title_full_unstemmed | Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review |
| title_short | Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review |
| title_sort | recent update on treatment and preventive modalities for covid 19 omicron variant b 1 1 529 in india a comprehensive review |
| topic | drugs options immune escape omicron pharmacotherapy vaccines |
| url | http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2022;volume=11;issue=2;spage=83;epage=90;aulast=Inder |
| work_keys_str_mv | AT deepinder recentupdateontreatmentandpreventivemodalitiesforcovid19omicronvariantb11529inindiaacomprehensivereview AT seemamanak recentupdateontreatmentandpreventivemodalitiesforcovid19omicronvariantb11529inindiaacomprehensivereview AT mdfaizakram recentupdateontreatmentandpreventivemodalitiesforcovid19omicronvariantb11529inindiaacomprehensivereview AT pawankumar recentupdateontreatmentandpreventivemodalitiesforcovid19omicronvariantb11529inindiaacomprehensivereview |